Advertisement

Mechanism of the Hypocalcemic Agent WR-2721 and Its Acute and Chronic Application in Eu- and Hyperparathyroidism

  • S. Hirschel-Scholz
  • J. Caverzasio
  • J.-P. Bonjour
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 208)

Abstract

Recent studies suggest that the organic phosphorothioate WR-2721 could be a useful drug in the treatment of hypercalcemia, particularly in relation with disorders of parathyroid hormone (PTH) homeostasis (1).

Keywords

Parathyroid Carcinoma Hypocalcemic Effect Thioic Acid Hypocalcemic Response Normal Parathyroid Function 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Glover, D., Riley,L., Carmichael, K., Spar, B., Glick, J., Kligerman, M., Agus, Z.S., Slatopolsky, E., Attie, M., and Goldfarb, S.: Hypocalcemia and inhibition of parathyroid hormone secretion after administration of WR-2721 (A radio-protective and chemoprotective agent). N.Engl.J.Med. 309: 1137 (1983).CrossRefGoogle Scholar
  2. 2.
    Yuhas, J.M.,Spellman, J.M., Culo, F.: The role of WR-2721 in radiotherapy and/or chemotherapy. Cancer Clin. Trials 3: 211 (1980).Google Scholar
  3. 3.
    Hirschel-Scholz, S., Jung, A., Fischer, J.A., Trechsel, U., and Bonjour, J.P.: Suppression of parathyroid secretion after administration of WR-2721 in a patient with parathyroid carcinoma. Clin. Endocrinol. 23: 313 (1985).CrossRefGoogle Scholar
  4. 4.
    Yuhas, J.M.: Biological factors affecting the radioprotective efficiency of S-2-[3-Aminopropylamino] Ethylphosphorothioic Acid (WR-2721). LD50 (30) doses. Radiation Res. 44: 621 (1970).CrossRefGoogle Scholar
  5. 5.
    Yuhas, J.M.: Protective drugs in cancer therapy: Optimal clinical testing and future directions. Radiation Oncol. Biol.Phys. 8: 513 (1982).Google Scholar
  6. 6.
    Durand, R.E.: Radioprotection by WR-2721 in vitro at low oxygen tensions: implications for its mechanisms of action. Br.J.Cancer 47: 387 (1983).CrossRefGoogle Scholar
  7. 7.
    Hirschel-Scholz, S., Caverzasio, J., Bonjour, J.-P.: Inhibition of parathyroid hormone (PTH) secretion and PTH-independent diminution of tubular Ca reabsorption by WR-2721, a unique hypocalcemic agent. J.Clin.Invest. in press (1985).Google Scholar
  8. 8.
    Attie, M.F., Fallon, M.D., Spar, B., Wolf, J.S., Slatopolsky, E., Goldfarb, S.: Bone and parathyroid inhibitory effects of S-2(3-aminopropylamino)ethylphosphorothioic acid. Studies in experimental animals and cultured bone cells. J.Clin.Invest. 75: 1191 (1985).CrossRefGoogle Scholar
  9. 9.
    Attie, M.F., Fallon, M.D., Spar, B., Wolf, J.S., Slatopolsky, E., Goldfarb, S.: Bone and parathyroid inhibitory effects of S-2(3-aminopropylamino)ethylphosphorothioic acid. Studies in experimental animals and cultured bone cells. J.Clin.Invest. 75: 1191 (1985).CrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1986

Authors and Affiliations

  • S. Hirschel-Scholz
    • 1
  • J. Caverzasio
    • 1
  • J.-P. Bonjour
    • 1
  1. 1.Division of Pathophysiology, Department of MedicineUniversity HospitalGeneva 4Switzerland

Personalised recommendations